Combinations of drugs that affect distinct mechanisms of HIV latency aim to induce robust
latency reversal leading to cytopathicity and elimination of the persistent HIV reservoir. Thus …

Current antiretroviral therapy (ART) provides potent suppression of HIV-1 replication.
However, ART does not target latent viral reservoirs, so persistent infection remains a …

Recently, there is considerable interest in the field of anti-HIV therapy to identify and develop
chromatin-modifying histone deacetylase (HDAC) inhibitors that can effectively reactivate …

Latent HIV persists in CD4+ T cells in infected patients under antiretroviral therapy (ART).
Latency is associated with transcriptional silencing of the integrated provirus and driven, at …

Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will
likely require effective drug combinations to achieve high levels of latency reversal. Using …

A long-lived latent reservoir of HIV-1-infected CD4 T cells persists with antiretroviral therapy
and prevents cure. We report that the emergence of latently infected primary CD4 T cells …

Histone deacetylases (HDACs) act on histones within the nucleosome-bound promoter of
human immunodeficiency virus type 1 (HIV-1) to maintain proviral latency. HDAC inhibition …

Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a
major obstacle to curing HIV infection. Pharmacological activation of HIV expression in …

Approaches to deplete persistent HIV infection are needed. We investigated the combined
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous …

Objectives: Chromatin-associated repression is one mechanism that maintains HIV-1
latency. Inhibition of histone deacetylases (HDAC) reverses this repression resulting in viral …